glp-1 gastric intestinal obstruction class action in west virginia and gastroparesis Safety Tolerability of Glucagon-Like Peptide-1 GASTROPARESIS RISK IN PATIENTS WITH – Patients Are Suing Over Alleged

The risk was determined to be greater with higher doses, extended use (seen in patients using Ozempic for more than a year), and when Ozempic was utilized for weight reduction

Unlike the other weight loss injections, that are GLP-1 receptor agonists, it has a powerful double action, being a GLP-1 and GIP receptor agonist." Dorianne Green, Medical Writer Clinical studies highlight impressive results: average weight losses of 15% at 5 mg, 19% at 10 mg, and 21% at 15 mg

They stimulate insulin secretion, inhibit glucagon release, and slow gastric emptying, which aids in lowering blood sugar levels and promotes satiety

Elevated blood sugar damages blood vessel walls, increases platelet reactivity, and impairs fibrinolysis

Nutrition for Connective Tissue Protein intake directly affects tissue rebuilding capacity